April 10, 2023

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

AMENDMENTS

GENITOURINARY, GYNECOLOGIC, LUNG

The following protocol amendments are in response to an NCI action letter for CTEP-supported studies that involve pembrolizumab. Please refer to study-specific instructions posted on CTSU.

• NRG-GU012: Amendment 1; protocol version date: February 20, 2023 (Accrual of new patients must be suspended until the IRB of record has reviewed and approved the amendment. Patients currently on study who are receiving pembrolizumab may continue on study provided they are informed of the new and/or modified risk information.)
• NRG-GY018: Amendment 12; protocol version date: February 24, 2023 (closed to accrual)
• NRG-GY020: Amendment 7; protocol version date: February 23, 2023 (closed to accrual)
• NRG-LU002: Amendment 9; protocol version date: February 22, 2023 (temporarily closed to accrual)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Join the next FORTE site call on May 17 at 4pm EDT, an informal discussion on study progress and conduct with the NRG FORTE team, featuring Kaiser Permanente representatives to share about their screening and enrolling process. Register today at this link!

3. GASTROINTESTINAL

NRG-GI005 (COBRA) / NRG-GI008 (CIRCULATE-US): The webinar “Surgical implications of ctDNA: Is this the future for colon cancer?” is being held on April 26 and May 4. Please visit the NRG Oncology website or see the memorandum posted on CTSU for details and how to register for one of the sessions.

4. GYNECOLOGIC

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-GY012 and NRG-GY023 – Reminder: BLOOD PRESSURE CUFF SUPPLY IS VERY LIMITED - Please be advised that VWR has a very limited supply of blood pressure cuffs at present. Please check your supplies on site for any overlooked cuffs prior to ordering. Thank you for your cooperation. 

Printing Biospecimen Transmittal PDFs on GYN Trials

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

5. HEAD & NECK

NRG-HN008 Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

6. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, May 3, 2023.

DRUG SAFETY UPDATES

Drug Safety updates have been issued for the following studies:

1. Request for NCORP PILOT Project Applications

Date Issued: February 17, 2023

Submission Due Date: April 21, 2023

NRG Oncology NCORP solicits PILOT projects addressing NRG NCORP Cancer Care Delivery Research (CCDR), Cancer Prevention and Control (CPC) Research and Health Disparities Research (HDR) priorities. PILOT projects should generate preliminary data and address feasibility issues to inform the development of a future NCORP concept. Refer to the links below for further details.

Cancer Care Delivery Research (CCDR)

Cancer Prevention and Control (CPC)

Health Disparities Research (HDR)

2. Register for the upcoming webinar hosted by the NRG Cancer Care Delivery Committee: Advancing equity in artificial intelligence for cancer care delivery

Cancer care delivery increasingly employs artificial intelligence tools to improve diagnosis, treatment selection, and health system efficiency. As tool integration progresses in clinical care settings, practitioners should be intentional about equitable implementation and knowledgeable about algorithmic fairness, which may exacerbate current health disparities. This webinar will address current artificial intelligence initiatives poised to promote fairness and health equity in optimizing cancer care delivery. This session will be held on April 26, 2023, 2 – 3:30pmEST and co-lead by Dr. Julian Hong of the University of California, San Francisco and Dr. Anant Madabhushi of Emory University. Please view the flyer here.

Click here to register for the webinar

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES

Rahman R, Polley MC, Alder L, Brastianos PK, Anders CK, Tawbi HA, Mehta M, Wen PY, Geyer S, de Groot J, Zadeh G, Piantadosi S, Galanis E, Khasraw M. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 2023 Apr;24(4):e161-e171. doi: 10.1016/S1470-2045(23)00005-0. PMID: 36990614. Read me.

Wang D, Harris J, Kraybill WG, Eisenberg B, Kirsch DG, Ettinger DS, Kane JM 3rd, Barry PN, Naghavi A, Freeman CR, Chen YL, Hitchcock YJ, Bedi M, Salerno KE, Severin D, Godette KD, Larrier NA, Curran WJ Jr, Torres-Saavedra PA, Lucas DR. Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. JAMA Oncol. 2023 Mar 30:e230042. doi: 10.1001/jamaoncol.2023.0042. Epub ahead of print. PMID: 36995690; PMCID: PMC10064284. Read me.

ACCEPTED ABSTRACTS – ASCO June 2-6, 2023

Corrigan KL, Paulus R, Klopp AH, Wenzel LB, Yeung AR, Thompson JS, Doncals DE, Kundapur V, Wiggers NH, Mohan DS, Ghamande SA, Westin SN, Schnarr KL, Haas ML, Gaffney DK, Waggoner SE, Vanderwall PJ, Jastaniyah NT, Pugh SL, Kachnic LA. Patient-reported outcomes during pelvic radiation therapy: a secondary analysis on sexual function from NRG-RTOG 1203.

Deek MP, Shetty AC, Song Y, Efstathiou JA, Feng FY, Shipley WU, Simko JP, Mouw KW, Miyamoto D, Pollack A, Michaelson MD, Zietman A, Coen JJ, Dahl DM, Jani AB, Souhami L, Chang BK, Lee RJ, Pugh SL, Tran PT. Prognostic Significance of Pretreatment Immune Cell Infiltration in Muscle Invasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712.

Hall WA, Karrison T, McGregor B, Barata P, Nagar H, Tang C, Shankar S, Morgan T, Lang JM, Kamran S, Glide-Hurst C, Sundaram KM, Katz S, Feng FY, McKay RR. NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).

Dasari A, Yu G, Kopetz S, Jacobs SA, Lucas PC, Sahin I, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree J, Wolmark N, Yothers G, George TJ, Lieu CH. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): NRG-GI008.

Morris VK, Yothers G, Kopetz S, Puhalla SL, Lucas PC, Iqbal A, Boland PM, Deming DA, Scott AJ, Lim HJ, Hong TS, Wolmark N, George TJ. Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

White J, Cecchini RS, Harris EER, Mamounas EP, Stover DG, Ganz PA, Jagsi R, Anderson SJ, Bergom C, Théberge V, El-Tamer M, Zellars RC, Shumway DA, Chen G-P, Julian TB, Wolmark N. NRG-BR007: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Please note the following upcoming meeting and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 14-19, 2023; Orlando, FL

American Association for Thoracic Surgery (AATS); May 6-9, 2023; Los Angeles, CA

American College of Radiology (ACR); May 6-10, 2023; Washington, DC

American Society of Clinical Oncology (ASCO); Jun 2-6, 2023; Chicago, IL

ESMO Breast Cancer Annual Congress; May 11-13, 2023; Berlin, Germany

European Society for Radiotherapy and Oncology (ESTRO); May 12-16, 2023; Vienna, Austria



Society for Clinical Trials (SCT); May 21-24, 2023; Baltimore, MD

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Society for Radiation Oncology (ASTRO); Oct 1-4, 2023; Chicago, IL; LBA Jul 12, 2023

ESMO World Congress on Gastrointestinal Cancer; Jun 28-Jul 1, 2023; Barcelona, Spain; LBA Jun 15, 2023

European Society of Gynaecological Oncology (ESGO); Sep 28-Oct 1, 2023; Istanbul, Turkey; due to publications committee Apr 24, 2023; meeting submission deadline May 8, 2023; LBA Aug 7, 2023

European Society for Medical Oncology (ESMO) Congress; Oct 20-24, 2023; Madrid, Spain; due to publications committee Apr 26, 2023; meeting submission deadline May 10, 2023, 9pm CntEurSummerTime (CEST); LBA Sep 14, 2023, 9pm CEST

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2023; Seoul, South Korea; due to publications committee Apr 24, 2023; meeting submission deadline May 8, 2023, Abstract & Film; TiP LBA, Aug 21, 2023

International Society for Quality-of-Life Research (ISOQOL); Oct 18-21, 2023; Calgary, AB Canada; LBA Jul 7, 2023

Radiological Society of North America (RSNA); Nov 27-Dec 1, 2023; Chicago, IL; due to publications committee Apr 19, 2023; meeting submission deadline; May 3, 2023, 12 Noon CT